SFA
ZYNE

Sequoia Financial Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sequoia Financial Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-49,700
Closed -$16.2K – 1021
2023
Q2 		$16.2K Buy
+49,700
New +$17.8K ﹤0.01% 963

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sequoia Financial Advisors's ZYNE Position: Q3 2023 in Review

Sequoia Financial Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 49,700 shares — an estimated $16.2K sold.

Sequoia Financial Advisors first reported a position in ZYNE in Q2 2023 and held it in 1 quarter. The position peaked at $16.2K in Q2 2023. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • Sequoia Financial Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Sequoia Financial Advisors sold 49,700 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $16.2K.
  • Sequoia Financial Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2023 and held it in 1 quarter.
  • Sequoia Financial Advisors's Zynerba Pharmaceuticals, Inc position peaked at $16.2K in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Sequoia Financial Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.